AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12468901 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (activities in a day-care-like setting once a week for 6 months)
Number of subjects: 25
Study 12468901 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 25
Study 9920062 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (3 or 6 microg/kg x day, s.c.) for 3 months
Number of subjects: 12
Study 7589392 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin
Number of subjects: 34
Study 7589392 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 2123791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 5 mg b.d. for 8 weeks followed by 10 mg b.d. for 8 weeks (Group I)
Number of subjects: 30
Study 2123791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg b.d. for 8 weeks followed by 20 mg b.d. for 8 weeks (Group II)
Number of subjects: 30
Study 2123791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 30
Study 6171989 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (beta-adrenoceptor stimulant)
Number of subjects: 22
Study 6171989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31288859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed distribution of a direct‐to‐patient educational brochure for chronic opioid use
Number of subjects: 0
Study 31288859 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28407990 — intervention group
Group type: EXPERIMENTAL
Intervention: New removable prosthesis insertion
Number of subjects: 30
Study 25674699 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline-Malate (CM) 8 g
Number of subjects: 14
Study 25674699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study 23092310 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aids depicting multimodal treatment options for colorectal cancer
Number of subjects: 367
Study 23092310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-treatment option with clear survival benefit
Number of subjects: 367
Study 23092310 — intervention group
Group type: EXPERIMENTAL
Intervention: Milder treatment option without survival benefit
Number of subjects: 367
Study 23092310 — intervention group
Group type: COMPARATOR
Intervention: Equally intense treatment options with different timing (neoadjuvant vs. adjuvant) without survival benefit
Number of subjects: 367
Study 19940729 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust manipulation
Number of subjects: 112
Study 19940729 — intervention group
Group type: COMPARATOR
Intervention: Nonthrust manipulation
Number of subjects: 112
Study 17516768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.70 g/kg)
Number of subjects: 106
Study 17516768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 14763496 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHD
Number of subjects: 18
Study 14763496 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHpost
Number of subjects: 18
Study 14763496 — intervention group
Group type: COMPARATOR
Intervention: CVVHpre
Number of subjects: 18
Study 11228365 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) vaccine, two doses at 6 and 9 months
Number of subjects: 365
Study 11228365 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) vaccine, one dose at 9 months
Number of subjects: 365
Study 11228365 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz (SW) vaccine, two doses at 6 and 9 months
Number of subjects: 365
Study 11228365 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz (SW) vaccine, one dose at 9 months
Number of subjects: 365
Study 11228365 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) vaccine, second dose
Number of subjects: 365
Study 11228365 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz (SW) vaccine, second dose
Number of subjects: 365
Study 11689734 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite male distance runners
Number of subjects: 25
Study 11689734 — intervention group
Group type: COMPARATOR
Intervention: Male university distance runners
Number of subjects: 25
Study 11689734 — intervention group
Group type: COMPARATOR
Intervention: Male untrained university students
Number of subjects: 25
Study 9140636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sedation (combination of haloperidol and diazepam, usually 20 mg of each)
Number of subjects: 495
Study 9140636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sedation
Number of subjects: 495
Study 7957410 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms inhaled oxitropium bromide (OB)
Number of subjects: 20
Study 7957410 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms inhaled fenoterol (F)
Number of subjects: 20
Study 7957410 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms inhaled fenoterol (F)
Number of subjects: 20
Study 3107660 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms at bedtime
Number of subjects: 142
Study 3107660 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 142
Study 1827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg twice daily, increased to 2.5 mg if necessary)
Number of subjects: 140
Study 1827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg twice daily, increased to 25 mg if necessary)
Number of subjects: 140
Study 1827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Isradipine and Captopril
Number of subjects: 140
Study 968036 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation treatment with total 1,500 rad mid-pelvic dose delivered on five consecutive days
Number of subjects: 14
Study 968036 — intervention group
Group type: COMPARATOR
Intervention: Conventional external irradiation technique of 5,000 rad delivered in 5 weeks
Number of subjects: 14
Study 30826492 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI + vortioxetine (10–20 mg/day)
Number of subjects: 151
Study 30826492 — intervention group
Group type: EXPERIMENTAL
Intervention: vortioxetine (10–20 mg/day) + placebo
Number of subjects: 151
Study 30826492 — intervention group
Group type: COMPARATOR
Intervention: current SSRI + placebo
Number of subjects: 151
Study 30826492 — intervention group
Group type: EXPERIMENTAL
Intervention: vortioxetine (10–20 mg/day)
Number of subjects: 151
Study 28842996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal packing
Number of subjects: 46
Study 28842996 — intervention group
Group type: COMPARATOR
Intervention: No pharyngeal packing
Number of subjects: 46
Study 27623234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 152
Study 27623234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 24433744 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Telehealth (HT)
Number of subjects: 60
Study 24433744 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care (CC)
Number of subjects: 60
Study 22914755 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-car bassinet
Number of subjects: 35
Study 22914755 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone bassinet
Number of subjects: 35
Study 22914755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 19439158 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 29
Study 19439158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 17489805 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose botulinum toxin A (BTX‐A)
Number of subjects: 39
Study 17489805 — intervention group
Group type: COMPARATOR
Intervention: Low-dose botulinum toxin A (BTX‐A)
Number of subjects: 39
Study 16189994 — intervention group
Group type: EXPERIMENTAL
Intervention: Food purchased from a village with < 10 microg/l arsenic in irrigation water
Number of subjects: 63
Study 16189994 — intervention group
Group type: COMPARATOR
Intervention: Food purchased from markets in the study village with > 100 microg/l arsenic in irrigation water
Number of subjects: 63
Study 16189994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 63
Study 16189994 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 16189994 — intervention group
Group type: EXPERIMENTAL
Intervention: Food from low-contamination area
Number of subjects: 63
Study 16189994 — intervention group
Group type: COMPARATOR
Intervention: Food from high-contamination area
Number of subjects: 63
Study 11914107 — intervention group
Group type: COMPARATOR
Intervention: alpha-tocopherol (100 mg/day)
Number of subjects: 400
Study 11914107 — intervention group
Group type: COMPARATOR
Intervention: alpha-carotene + beta-carotene (15 mg/day)
Number of subjects: 400
Study 11914107 — intervention group
Group type: COMPARATOR
Intervention: lutein (from marigold extracts)
Number of subjects: 400
Study 11914107 — intervention group
Group type: COMPARATOR
Intervention: lycopene (from tomato paste)
Number of subjects: 400
Study 9860093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured resin composite luting agent
Number of subjects: 27
Study 9860093 — intervention group
Group type: COMPARATOR
Intervention: Chemically cured resin composite luting agent
Number of subjects: 27
Study 7840078 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat extract containing 1% soluble beta-glucans
Number of subjects: 23
Study 7840078 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat extract containing 10% soluble beta-glucans
Number of subjects: 23
Study 7840078 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat extracts (1% and 10%)
Number of subjects: 23
Study 7840078 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat extracts
Number of subjects: 23
Study 2205188 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ethinyloestradiol gel
Number of subjects: 25
Study 2205188 — intervention group
Group type: COMPARATOR
Intervention: gel alone (control)
Number of subjects: 25
Study 652210 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tents used as an adjunct to labor induction
Number of subjects: 74
Study 652210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laminaria)
Number of subjects: 74
Study 31373615 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (tested for anti-EBV antibodies)
Number of subjects: 70296
Study 31373615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 70296
Study 28449886 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-channel device (ApneaLink [AL], ResMed, UK) used for remote postal-based diagnostic service.
Number of subjects: 733
Study 25881456 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan treatment group (80 mg per day, once daily)
Number of subjects: 204
Study 25881456 — intervention group
Group type: COMPARATOR
Intervention: SG treatment group (5 g each time, 3 times per day)
Number of subjects: 204
Study 25881456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SG and telmisartan treatment group (telmisartan 80 mg per day, once daily and SG 5 g each time, 3 times per day)
Number of subjects: 204
Study 25881456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SG and telmisartan treatment group
Number of subjects: 204
Study 24029859 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise programme
Number of subjects: 87
Study 24029859 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg rise tests
Number of subjects: 87
Study 24029859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical hop results
Number of subjects: 87
Study 21335417 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy
Number of subjects: 6182
Study 21335417 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole→Tamoxifen
Number of subjects: 6182
Study 21335417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen→Letrozole
Number of subjects: 6182
Study 21335417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen monotherapy
Number of subjects: 6182
Study 18570223 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Practice Nurse (APN) intervention for 6 months
Number of subjects: 123
Study 18570223 — intervention group
Group type: EXPERIMENTAL
Intervention: APN plus Psychiatric Consultation-Liaison Nurse (PCLN) intervention
Number of subjects: 123
Study 18570223 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (symptom management by a research assistant)
Number of subjects: 123
Study 17536207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness intervention focusing on functional skills, strength, endurance and flexibility
Number of subjects: 217
Study 17536207 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor intervention focusing on body awareness, body experience and coordination
Number of subjects: 217
Study 17536207 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 217
Study 15593039 — intervention group
Group type: EXPERIMENTAL
Intervention: BK-F Polymethylmethacrylate-based hemodialysis (BK-F-HD)
Number of subjects: 18
Study 15593039 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis (LF-HD)
Number of subjects: 18
Study 12143075 — intervention group
Group type: EXPERIMENTAL
Intervention: PLST intervention
Number of subjects: 0
Study 12143075 — intervention group
Group type: COMPARATOR
Intervention: Comparison intervention
Number of subjects: 0
Study 9562692 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa‐HB vaccine administered at 2, 4, and 6 months (group A)
Number of subjects: 565
Study 9562692 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa‐HB vaccine administered at 3, 5, and 11 months (group B)
Number of subjects: 565
Study 7708996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) at 8 cmH2O
Number of subjects: 16
Study 7708996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 16
Study 7708996 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure
Number of subjects: 16
Study 2505631 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 77
Study 2505631 — intervention group
Group type: COMPARATOR
Intervention: halothane
Number of subjects: 77
Study 2505631 — intervention group
Group type: COMPARATOR
Intervention: enflurane
Number of subjects: 77
Study 1146927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol (EE) at 50 mug per day
Number of subjects: 4638
Study 1146927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol at 50 mug per day
Number of subjects: 4638
Study 1146927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of very low doses (20 to 40 mug per day) of estrogen with various 19-nor progestins
Number of subjects: 4638
Study 1146927 — intervention group
Group type: COMPARATOR
Intervention: Control cycles (no treatment)
Number of subjects: 4638
Study 30844728 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker titration (bisoprolol and carvedilol)
Number of subjects: 574
Study 30158384 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) 1 mg
Number of subjects: 40
Study 30158384 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) 2 mg
Number of subjects: 40
Study 30158384 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) 4 mg
Number of subjects: 40
Study 30158384 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) 8 mg
Number of subjects: 40
Study 30158384 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium) for 7 days
Number of subjects: 40
Study 30158384 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-104-NP (pitavastatin calcium)
Number of subjects: 40
Study 27063525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless cryopreserved amniotic membrane graft (Prokera)
Number of subjects: 40
Study 27063525 — intervention group
Group type: COMPARATOR
Intervention: Bandage contact lens (Acuvue Oasys)
Number of subjects: 40
Study 25213566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 3 months
Number of subjects: 53
Study 25213566 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 53
Study 22328479 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshop on EMR documentation with embedded social marketing messages
Number of subjects: 155
Study 20298497 — intervention group
Group type: EXPERIMENTAL
Intervention: certolizumab pegol 400 mg (week 0, 2, 4)
Number of subjects: 668
Study 20298497 — intervention group
Group type: EXPERIMENTAL
Intervention: certolizumab pegol 400 mg every 4 weeks until week 24
Number of subjects: 668
Study 20298497 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 668
Study 18069214 — intervention group
Group type: EXPERIMENTAL
Intervention: eMPC algorithm
Number of subjects: 20
Study 18069214 — intervention group
Group type: COMPARATOR
Intervention: RP group
Number of subjects: 20
Study 15714292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lay-open technique (Group A)
Number of subjects: 142
Study 15714292 — intervention group
Group type: COMPARATOR
Intervention: Excision with primary closure (Group B)
Number of subjects: 142
Study 11847615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coating
Number of subjects: 20
Study 11847615 — intervention group
Group type: COMPARATOR
Intervention: Non-coated stems (Control)
Number of subjects: 20
Study 9437314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.02 mg/ml)
Number of subjects: 50
Study 9437314 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin solution (0.3%)
Number of subjects: 50
Study 9437314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 50
Study 7906330 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 32
Study 7906330 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 32
Study 2698568 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg gallopamil (slow release) twice daily
Number of subjects: 35
Study 2698568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 779497 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 150
Study 779497 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 150
Study 779497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and psychotherapy
Number of subjects: 150
Study 29984439 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline pH 7.0
Number of subjects: 17
Study 29984439 — intervention group
Group type: COMPARATOR
Intervention: terbutaline pH 4.3
Number of subjects: 17
Study 29984439 — intervention group
Group type: COMPARATOR
Intervention: saline solution pH 7.0
Number of subjects: 17
Study 29984439 — intervention group
Group type: COMPARATOR
Intervention: saline solution pH 4.3
Number of subjects: 17
Study 28726510 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS)
Number of subjects: 537
Study 28726510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 26247913 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning supported Train-the-Trainer program
Number of subjects: 566
Study 26247913 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation (control)
Number of subjects: 566
Study 23245824 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) given immediately after BTX-A injections
Number of subjects: 0
Study 23245824 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation (ES) given immediately after BTX-A injections
Number of subjects: 0
Study 21962476 — intervention group
Group type: EXPERIMENTAL
Intervention: Precontrast HiSS MRI
Number of subjects: 54
Study 21962476 — intervention group
Group type: COMPARATOR
Intervention: Conventional fat-suppressed MRI
Number of subjects: 54
Study 18503840 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct coronal images (DC)
Number of subjects: 0
Study 18503840 — intervention group
Group type: COMPARATOR
Intervention: Coronal reformatted images with 1-mm axial collimation (CR1)
Number of subjects: 0
Study 18503840 — intervention group
Group type: COMPARATOR
Intervention: Coronal reformatted images with 0.625-mm axial collimation (CR2)
Number of subjects: 0
Study 16371497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) at 5.4 J per point, power density 20 mW/cm2
Number of subjects: 7
Study 16371497 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT (0 J)
Number of subjects: 7
Study 12748498 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 32
Study 12748498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10921707 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits
Number of subjects: 42
Study 10921707 — intervention group
Group type: COMPARATOR
Intervention: Uncoated cardiopulmonary bypass circuits
Number of subjects: 42
Study 8822400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex education program based on cognitive social learning theory and social influence theory
Number of subjects: 2411
Study 8822400 — intervention group
Group type: COMPARATOR
Intervention: Pretest
Number of subjects: 2411
Study 8822400 — intervention group
Group type: COMPARATOR
Intervention: Intervention
Number of subjects: 2411
Study 8079476 — intervention group
Group type: EXPERIMENTAL
Intervention: autohemotransfusions of ultraviolet‐irradiated blood (UVIB)
Number of subjects: 85
Study 2485053 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-human ANP, 150 micrograms over 30 min
Number of subjects: 6
Study 2485053 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-human ANP after acute CE inhibition by enalapril (EN) 20 mg P.O., 4 h before ANP infusion
Number of subjects: 6
Study 2485053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31172685 — intervention group
Group type: EXPERIMENTAL
Intervention: AG10
Number of subjects: 0